← Back
Data updated: Jun 28, 2026
SQUARE PHARMS
Generics Pharmaceuticals
SQUARE PHARMS is a generic drug manufacturer with 3 FDA-approved products.
2018
Since
3
Drugs
-
Trials
0
New Drugs (2yr)
SQUARE PHARMS's Key Drugs
SQUARE PHARMS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
No active drugs
SQUARE PHARMS's Recent FDA Approvals
New NDA/BLA approvals for SQUARE PHARMS over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
SQUARE PHARMS's Therapeutic Areas
Disease areas where SQUARE PHARMS has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
SQUARE PHARMS Pipeline Snapshot
Active clinical trials for SQUARE PHARMS across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2018-08-28
- Latest
- 2025-01-24
- Applications
- 3